SARAH FUGATE: Open Payments
NPI 1437644424 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,089 in 71 payments from 11 companies in 2025. Trend: 2023 $861 · 2024 $1,034 · 2025 $1,089
Food & beverage: $1,088Education: $1
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $347 |
| Vanda Pharmaceuticals Inc. | 21 | $273 |
| ABBVIE INC. | 11 | $151 |
| Lundbeck LLC | 6 | $108 |
| Axsome Therapeutics, Inc. | 4 | $80 |
| Lilly USA, LLC | 2 | $36 |
| Alkermes, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
Products named: REXULTI, HETLIOZ, VRAYLAR, Auvelity, FANAPT, MOUNJARO, LYBALVI, CAPLYTA.
Industry payments across KY — which companies pay providers there.
